Detalhe da pesquisa
1.
Rebound Phenomenon After Nirmatrelvir/Ritonavir Treatment of Coronavirus Disease 2019 (COVID-19) in High-Risk Persons.
Clin Infect Dis
; 76(3): e537-e539, 2023 02 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-35698452
2.
Monoclonal Antibody Treatment of Breakthrough COVID-19 in Fully Vaccinated Individuals with High-Risk Comorbidities.
J Infect Dis
; 225(4): 598-602, 2022 02 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-34791298
3.
Comparable Outcomes for Bebtelovimab and Ritonavir-Boosted Nirmatrelvir Treatment in High-Risk Patients With Coronavirus Disease-2019 During Severe Acute Respiratory Syndrome Coronavirus 2 BA.2 Omicron Epoch.
J Infect Dis
; 226(10): 1683-1687, 2022 11 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-36124696
4.
Real-World Clinical Outcomes of Bamlanivimab and Casirivimab-Imdevimab Among High-Risk Patients With Mild to Moderate Coronavirus Disease 2019.
J Infect Dis
; 224(8): 1278-1286, 2021 10 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-34279629
5.
Telemonitoring Blood Pressure by Secure Message on a Patient Portal: Use, Content, and Outcomes.
Telemed J E Health
; 21(8): 630-6, 2015 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-25885765
6.
Telemedicine barriers associated with regional quality measures.
Telemed J E Health
; 20(2): 179-81, 2014 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-24205836
7.
Impact of patient portal secure messages and electronic visits on adult primary care office visits.
Telemed J E Health
; 20(3): 192-8, 2014 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-24350803
8.
Comparable outcomes of outpatient remdesivir and sotrovimab among high-risk patients with mild to moderate COVID-19 during the omicron BA.1 surge.
Sci Rep
; 14(1): 5430, 2024 03 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-38443438
9.
Outpatient treatment with concomitant vaccine-boosted convalescent plasma for patients with immunosuppression and COVID-19.
mBio
; 15(5): e0040024, 2024 May 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-38602414
10.
Patient preferences for telehealth services in a large multispecialty practice.
J Telemed Telecare
; 29(4): 298-303, 2023 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-33461397
11.
Should you search the Internet for information about your acute symptom?
Telemed J E Health
; 18(3): 213-8, 2012 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-22364307
12.
Real-world Clinical Outcomes of Bebtelovimab and Sotrovimab Treatment of High-risk Persons With Coronavirus Disease 2019 During the Omicron Epoch.
Open Forum Infect Dis
; 9(10): ofac411, 2022 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-36213724
13.
Curbing the Delta Surge: Clinical Outcomes After Treatment With Bamlanivimab-Etesevimab, Casirivimab-Imdevimab, or Sotrovimab for Mild to Moderate Coronavirus Disease 2019.
Mayo Clin Proc
; 97(9): 1641-1648, 2022 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-36058578
14.
Effectiveness of Monoclonal Antibodies in Preventing Severe COVID-19 With Emergence of the Delta Variant.
Mayo Clin Proc
; 97(2): 327-332, 2022 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-35120695
15.
Are e-health web users looking for different symptom information than callers to triage centers?
Telemed J E Health
; 17(1): 19-24, 2011.
Artigo
em Inglês
| MEDLINE | ID: mdl-21214306
16.
COVID-19 Care Clinic in a Medical Center: Lessons Learned.
J Prim Care Community Health
; 12: 21501327211056796, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-34872410
17.
A mobile unit overcomes the challenges to monoclonal antibody infusion for COVID-19 in skilled care facilities.
J Am Geriatr Soc
; 69(4): 868-873, 2021 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-33619724
18.
Association of Intravenous Bamlanivimab Use with Reduced Hospitalization, Intensive Care Unit Admission, and Mortality in Patients with Mild to Moderate COVID-19.
medRxiv
; 2021 May 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-34075387
19.
Casirivimab-Imdevimab treatment is associated with reduced rates of hospitalization among high-risk patients with mild to moderate coronavirus disease-19.
EClinicalMedicine
; 40: 101102, 2021 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-34485873
20.
Intravenous bamlanivimab use associates with reduced hospitalization in high-risk patients with mild to moderate COVID-19.
J Clin Invest
; 131(19)2021 10 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34411003